{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:40:22Z","timestamp":1787755222146,"version":"build-2784847793"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010264","name":"Prevent Blindness","doi-asserted-by":"publisher","award":["P30-EY026877"],"award-info":[{"award-number":["P30-EY026877"]}],"id":[{"id":"10.13039\/100010264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40123-026-01439-5","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:34:56Z","timestamp":1783758896000},"page":"3177-3180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Response to: Letter to the Editor Regarding \u201cAflibercept 8\u00a0mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials\u201d"],"prefix":"10.1007","volume":"15","author":[{"given":"Scott M.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kuznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mojebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Keeping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"11","key":"1439_CR1","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1007\/s40123-025-01247-3","volume":"14","author":"SM Friedman","year":"2025","unstructured":"Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, et\u00a0al. Aflibercept 8 mg versus faricimab treat-and-extend for diabetic macular edema or neovascular age-related macular degeneration: a Bayesian fixed-effect network meta-analysis of clinical trials. Ophthalmol Ther. 2025;14(11):2919\u201336. https:\/\/doi.org\/10.1007\/s40123-025-01247-3.","journal-title":"Ophthalmol Ther"},{"key":"1439_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-026-01440-y","author":"GD Panos","year":"2026","unstructured":"Panos GD. Letter to the Editor regarding \u201cAflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials\u201d. Ophthalmol Ther. 2026. https:\/\/doi.org\/10.1007\/s40123-026-01440-y.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"1439_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ophtha.2025.10.028","volume":"133","author":"DV Do","year":"2026","unstructured":"Do DV, Wykoff CC, Sivaprasad S, et\u00a0al. Intravitreal aflibercept 8 mg for diabetic macular edema: ninety-six-week results from the randomized phase 2\/3 PHOTON trial. Ophthalmology. 2026;133(5):577\u201388. https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.028.","journal-title":"Ophthalmology"},{"issue":"1","key":"1439_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, Lanzetta P, Leal S, et\u00a0al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: ninety-six-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2026;133(1):39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022.","journal-title":"Ophthalmology"},{"issue":"10326","key":"1439_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et\u00a0al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(22)00018-6.","journal-title":"Lancet"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01439-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01439-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:31Z","timestamp":1787751571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01439-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01439-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"12 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Scott M. Friedman has received grants or contracts from Bayer, JAEB Center, Ophthea, Regeneron Pharmaceuticals, Inc., Genentech, Amgen, Clearside Biomedical, EyePoint, ONL Therapeutics, REGENXBIO, Kowa, Kodiak Sciences, and Belite Bio, has participated on a Data Safety Monitoring Board or Advisory Board for Amgen, Genentech, and Ocular Therapeutics, and has stock or stock options in REvOpsis. Yingxin Xu, Andreas Kuznik, and Steven Sherman are employees and stockholders of Regeneron Pharmaceuticals, Inc. Ali Mojebi, Sam Keeping, and Keith Chan are employees of Precision AQ, which received funding from Regeneron Pharmaceuticals, Inc. for conducting this analysis. Theodore Leng has received funding from Astellas and served as a consultant for Astellas, Boehringer Ingelheim, Roche\/Genentech, Topcon, Toku, and Virtual Field. Nimesh Patel has served as an advisor for Alcon, Alimera, Allergan, Apellis, Biogen, DORC, EyePoint, Genentech, Kyoto Drug Company, Regeneron Pharmaceuticals, Inc., and REGENXBIO.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}